Assertio raises tender offer price to $21.80 per share in Garda deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Assertio Announces Amended and Restated Merger Agreement with Garda Therapeutics
May 4, 2026 8:00 AM EDTIncreased All-Cash Tender Offer Price of $21.80 per share or $153.2 Million
New Tender Offer Price Represents 21.1% Premium to Prior Offer
LAKE FOREST, Ill.--(BUSINESS WIRE)-- Assertio Holdings, Inc. (Nasdaq: ASRT) (Assertio or the Company) today announced that, on May 1, 2026, Assertio and Garda Therapeutics (Garda) entered into an Amended and Restated Agreement and Plan of Merger (the Merger Agreement), pursuant to which Garda has increased its offer to acquire all outstanding shares of Assertio to $21.80 per share in cash with no contingent value right.
The increased offer... More
